名稱 | BCR(E13)-ABL1(E2)_P210 Fusion |
型號(hào) | CBP20207R |
報(bào)價(jià) | ![]() |
特點(diǎn) | BCR(E13)-ABL1(E2)_P210 Fusion |
產(chǎn)品搜索
相關(guān)文章
- 淺談NTRK fusion
- RNA-Fusion Cocktail再升級(jí)
- 【產(chǎn)品推介】TIGIT靶點(diǎn)細(xì)胞篩選模型
- 攝入全谷類食物能明顯降低患結(jié)直腸癌的風(fēng)險(xiǎn)
- 有關(guān)細(xì)胞株生長要考慮的因素
- 腫瘤免疫藥靶細(xì)胞模型系列——GITR
- 川大華西CRISPR研究再獲新進(jìn)展
- 認(rèn)識(shí)一下北京細(xì)胞庫的檢測(cè)項(xiàng)目
- 三陰性乳腺癌的一個(gè)突破口——BRCA基因檢測(cè)?
- 從諾輝財(cái)報(bào)看甲基化市場(chǎng),科佰生物助力甲基化標(biāo)準(zhǔn)品的開發(fā)
聯(lián)系我們
聯(lián)系人:蔣經(jīng)理
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
基因檢測(cè)標(biāo)準(zhǔn)品 > Fusion > CBP20207RBCR(E13)-ABL1(E2)_P210 Fusion

- 詳細(xì)內(nèi)容
CBP20207R | |
Format | RNA |
Description | Presence of a BCR-ABL1 fusion gene is necessary for the pathogenesis of CML. In up to 95% of cases, a t(9;22) (q34;q11) translocation results in the BCR-ABL1 fusion gene (Faderl et al. 1999). This translocation results in the Philadephia chromosome. In rare CML cases lacking the traditional t(9;22) translocation, other translocations result in the creation of the BCR-ABL1 fusion gene, which sometimes involve multiple chromosomes. |
Technical Data | |
Left Gene | BCR |
Right Gene | ABL1 |
Left Breakpoint | chr22:23631808:+(hg19) |
Right Breakpoint | chr9:133729451:+(hg19) |
Buffer | Tris-EDTA |
Product Information | |
Intended Use | Research Use Only |
Unit Size | 1ug |
Concentration | Download for COA |
Purity | Download for COA |
RNA electrophoresis | Download for COA |
Sanger sequencing | |
Storage | -80℃ |
Expiry | 12 months from the date of manufacture |